Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A new study finds that PROTAC cancer drugs — designed to destroy harmful proteins — work better when proteins pile up due to poor breakdown rather than overproduction. The findings could help predict which tumors respond best to these therapies, paving the way for more personalized cancer treatment.
A new study from the University of Edinburgh sheds light on why some tumors may respond better than others to a cutting-edge class of cancer drugs called PROTACs (Proteolysis Targeting Chimeras). Unlike traditional drugs that merely block harmful proteins, PROTACs are designed to eliminate them entirely by hijacking the cell's own waste-disposal system — a potentially more powerful approach for cancers driven by protein overload.
The key finding? Why a protein accumulates matters just as much as how much of it is present. Using β-catenin — a protein implicated in many cancers — researchers showed that PROTACs were highly effective when the protein built up due to faulty breakdown, reducing levels to a consistent minimum regardless of the starting amount. But when cancer cells were simply producing more protein, treatment left elevated levels behind because new protein kept being made.
Key Takeaways:
Why it matters: As PROTACs move closer to clinical use, understanding the biological "why" behind protein accumulation could help oncologists identify which patients are most likely to benefit — making treatment smarter, not just stronger.
